1. Scrip
  2. >>Business

TB Alliance CEO On Derailed Treatment In Ukraine, Pediatric Pretomanid Plans

 
• By Anju Ghangurde

TB Alliance CEO Mel Spigelman discusses the huge disruptions in TB treatment in war-ravaged Ukraine, and need for funding, political will and resources along the lines of that galvanized for COVID-19, or "even a fraction" of that, to control the deadly infectious disease. He also touched on the accelerated availability of the BPaL regimen and a partnered program for an anti-TB natural product.

TB
COVID-19 And The Russia-Ukraine Conflict Set Back TB Control Efforts • Source: Alamy

COVID-19 has wiped out years of progress in tackling the global burden of tuberculosis (TB) and the Russia-Ukraine conflict only makes things worse for patients in the region which has a high burden of drug-resistant TB. Globally, 2020 saw the first year-over-year increase (of over 5%) in deaths from TB since 2005.

In a wide-ranging interview with Scrip, Dr Mel Spigelman, president and CEO of the TB Alliance, discussed the distressing on-ground situation for people with TB in Ukraine, why there needs to be an Operation Warp Speed-like initiative for the killer infectious disease that afflicts over 10 million people each year and also where things stand for the not-for-profit organization’s pretomanid study in children

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.